Track topics on Twitter Track topics that are important to you
DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER™ Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the ORADUR™ sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the TRANSDUR™ transdermal patch technology, the DURIN™ Biodegradable Implant (drug-loaded implant system) and the MICRODUR™ Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which four are in collaboration with pharmaceutical partners. DURECT’s strategy is to capitalize on the wealth of opportunities afforded by our proprietary platform technologies in three ways: To internally develop promising products based on our technologies To partner some of our product opportunities with development and/or commercialization partners at appropriate stages along the development timelines; and To make our technologies, along with our pre-clinical and clinical development expertise available to partners with the desire to develop proprietary extended or controlled release formulations of a wide range of molecules.
2 Results Way
United States of America
Fax: 408 777 3577
DURECT's Posimir (SABER - Bupivacaine) for post-surgical pain failed its Phase III clinical trial.
Indivior PLC purchased certain US patent rights from Durect Corp., which primarily develops delivery technologies for its pipeline of CNS-focused approved active agents, with the goal of enhancing the...
US-based biopharmaceutical company Durect has concluded patient enrolment in its Phase III PERSIST clinical trial of Posimir (Saber-Bupivacaine) for pain relief following surgery.
DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic de...
We have published hundreds of Durect news stories on BioPortfolio along with dozens of Durect Clinical Trials and PubMed Articles about Durect for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Durect Companies in our database. You can also find out about relevant Durect Drugs and Medications on this site too.
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...